샘플 요청 목록

 카트 문의
시장보고서
상품코드
1701263

세계의 결핵 진단 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By Type (Detection Of Latent Infection, Phage Assay, Nucleic Acid Testing), By End-use (Diagnostic Laboratories, Hospitals & Clinic), By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

결핵 진단 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 결핵 진단 시장 규모는 2025년부터 2030년까지 5.8%의 연평균 복합 성장률(CAGR)을 나타내고, 2030년까지 31억 8,000만 달러에 달할 것으로 예측됩니다.

인터페론γ 방출 분석법(IGRA), 혈청학적 방법, 핵산검사 등 첨단 진단법의 등장으로 진단약의 사용률이 높아지고 있습니다. 또한, 항원 분석과 같은 POC(Point of Care) 기술도 결핵 진단율을 높이고 있습니다.

POC 진단을 포함한 이러한 고급 방법은 저렴하고 정확하고 간편하며 빠른 결과를 얻을 수 있습니다. 또한, 결핵의 부담 증가가 시장 성장의 주요 요인으로 작용하고 있습니다. 세계보건기구(WHO)에 따르면 2014년 전 세계 결핵 환자 수는 약 960만 명으로 추산됩니다. 이러한 높은 유병률로 인해 정부, 의료 기관, 연구 기관 및 시장 관계자들은 이 전염병의 발생을 억제하기 위한 노력을 시작했습니다.

고부담 지역에서의 검진율 증가, 저렴한 가격의 진단약, 고도의 조사방법, 신속한 임상판단, 사망률 감소가 개발의 초점이 되고 있습니다. 예방적 및 치료적 진단율의 향상은 이러한 노력의 최종 결과입니다. 이에 따라 진단 검사에 대한 수요가 급증하고 결핵 진단 시장이 확대되고 있습니다.

결핵 진단 시장 보고서 하이라이트

  • 잠복 감염 검출 분야(피부 검사 및 IGRA)는 결핵 유병률 증가에 힘입어 2024년 40.59%의 점유율로 시장을 주도했습니다.
  • 약제 내성(DST)은 예측 기간 동안 가장 빠른 CAGR을 달성할 것으로 예상되며, DST는 다양한 항생제에 대한 결핵균의 감수성을 평가하여 어떤 약물이 치료에 효과적인지 확인합니다.
  • 2024년에는 진단 실험실 부문이 결핵 진단 시장에서 가장 큰 매출 점유율을 차지하여 그 원동력이 되었습니다.
  • 병원 및 클리닉 분야는 헬스케어 환경에서의 결핵 검사율 상승에 힘입어 크게 성장할 것으로 예측됩니다.
  • 아시아태평양 결핵 진단 시장은 2024년 37.18%의 매출 점유율로 시장을 장악했고, 예측 기간 동안 가장 빠르게 성장할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 결핵 진단 시장 변수, 동향, 범위

  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
    • 시장 기회 분석
  • 결핵 진단 시장 분석 툴
    • 업계 분석 - Porter의 Five Forces 분석
    • PESTEL 분석
    • COVID-19의 영향 분석
    • 사례 연구

제4장 결핵 진단 시장 : 유형별 추정·동향 분석

  • 유형별 시장 점유율, 2024년과 2030년
  • 부문 대시보드
  • 세계의 결핵 진단 시장 : 유형별 전망
  • 잠재 감염 감지(피부 테스트 및 IGRA)
  • 파지 어세이
  • 약제 내성 감지(DST)
  • 핵산 검사
  • 방사선학적 방법
  • 사이토카인 감지 어세이
  • 기타

제5장 결핵 진단 시장 : 최종 용도별 추정·동향 분석

  • 최종 용도 시장 점유율, 2024년 및 2030년
  • 부문 대시보드
  • 세계의 결핵 진단 시장 : 최종 용도별 전망
  • 진단실험실
  • 병원 및 진료소
  • 기타

제6장 결핵 진단 시장 : 지역별 추정·동향 분석, 제품별, 유형별, 최종 용도별

  • 지역별 시장 점유율 분석, 2024년 및 2030년
  • 지역 시장 대시보드
  • 세계 지역 시장 스냅숏
  • 시장 규모와 예측 동향 분석, 2018-2030년까지 :
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제7장 경쟁 구도

  • 주요 시장 진출기업의 최근 동향과 영향 분석
  • 기업/경쟁 분류
  • 주요 기업의 시장 점유율/포지션 분석, 2024년
  • 기업 개요
    • Abbott
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • BD
    • F. Hoffmann-La Roche AG
    • Hologic, Inc.
    • Cepheid
    • DiaSorin SpA
    • Hain Lifescience GmbH
    • Oxford Immunotec
LSH 25.05.15

Tuberculosis Diagnostics Market Growth & Trends:

The global tuberculosis diagnostics market size is expected to reach USD 3.18 billion by 2030, registering a CAGR of 5.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Advent of advanced diagnostic methods such as Interferon-gamma Release Assay (IGRA), serological methods, and nucleic acid testing have resulted in the high usage rate of diagnostics. Moreover, Point of Care (POC) technologies such as antigen assays are also promoting the diagnosis rate of TB.

These advanced methods including POC diagnostics are affordable, accurate, simple, and yield quick results. Furthermore, the rising burden of TB is the primary factor responsible for the lucrative market growth. As per the World Health Organization, the global estimates of patients afflicted with TB were around 9.6 million in 2014. This high prevalence rate has led the government, healthcare organizations, research institutes, and market players to initiate endeavors directed toward containing the incidence of this infectious disease.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This has led to a subsequent upsurge in the demand for diagnostic tests and the TB diagnostics market.

Tuberculosis Diagnostics Market Report Highlights:

  • The latent infection detection segment (Skin Test & IGRA) led the market in 2024 with a 40.59% share, driven by the increasing prevalence of tuberculosis.
  • Drug Resistance (DST) is projected to achieve the fastest CAGR during the forecast period. DST evaluates the susceptibility of Mycobacterium tuberculosis to various antibiotics, identifying which drugs are effective for treatment.
  • In 2024, the diagnostic laboratories segment dominated the TB diagnostics market with the largest revenue share, driven by initiatives to enhance patient outcomes through accessible, retail-level diagnostic services.
  • The hospitals and clinics segment is poised for significant growth, driven by increasing TB testing rates in healthcare settings.
  • The tuberculosis diagnostics market in Asia Pacific dominated the market with revenue share of 37.18% in 2024 and is expected to witness the fastest growth over the forecast period.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Tuberculosis Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market driver analysis
    • 3.1.2. Market restraint analysis
    • 3.1.3. Market opportunities analysis
  • 3.2. Tuberculosis Diagnostics Market Analysis Tools
    • 3.2.1. Industry Analysis - Porter's
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTEL Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic landscape
      • 3.2.2.3. Social landscape
      • 3.2.2.4. Technological landscape
      • 3.2.2.5. Environmental landscape
      • 3.2.2.6. Legal landscape
    • 3.2.3. COVID-19 Impact Analysis
    • 3.2.4. Case Studies

Chapter 4. Tuberculosis Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Tuberculosis Diagnostics Market by Type Outlook
  • 4.4. Detection of Latent Infection (Skin Test & IGRA)
    • 4.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.5. Phage Assay
    • 4.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.6. Detection of Drug Resistance (DST)
    • 4.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.7. Nucleic Acid Testing
    • 4.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.8. Radiographic Method
    • 4.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.9. Cytokine Detection Assay
    • 4.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 5. Tuberculosis Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Tuberculosis Diagnostics Market by End Use Outlook
  • 5.4. Diagnostic Laboratories
    • 5.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 5.5. Hospitals & Clinics
    • 5.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 6. Tuberculosis Diagnostics Market: Regional Estimates & Trend Analysis, By Product, By Type, By End Use

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share/position analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Abbott
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Technology Type benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. QIAGEN
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Technology Type benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Thermo Fisher Scientific Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Technology Type benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. BD
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Technology Type benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. F. Hoffmann-La Roche AG
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Technology Type benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Hologic, Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Technology Type benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Cepheid
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Technology Type benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. DiaSorin S.p.A.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Technology Type benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Hain Lifescience GmbH
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Technology Type benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Oxford Immunotec
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Technology Type benchmarking
      • 7.4.10.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제